NCT02930941.

Trial name or title	Topical intranasal tranexamic acid for epistaxis in the emergency department
Methods	Randomised, double‐blind, single‐centre, placebo‐controlled trial
Participants	Adults (> 18) with anterior epistaxis
Interventions	Intervention group: tranexamic acid (100 mg/1 mL) sprayed in to the affected nostril(s) via intranasal atomisation device; may repeat 2 doses in each affected nostril(s) Comparator group: 0.9% sodium chloride (1 mL)
Outcomes	Primary outcome measure: Time to control of bleeding (7 days) Secondary outcome measures: Length of stay in the emergency department Re‐bleeding within the first 24 hours Re‐bleeding within the first week Incidence of thromboembolic events (7 days) Incidence of drug‐related events (7 days)
Starting date	February 2016
Contact information	Principal investigator: Aimee Moulin MD, University of California, Davis (akmoulin@ucdavis.edu)
Notes	Estimated study completion date: December 2019